RobertBLorsbachMD
Pathology • Cincinnati, OHHematopathology, Anatomic Pathology, Clinical Pathology
Associate Professor, Pathology, University of Arkansas COM
Dr. Lorsbach is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
3333 Burnet Ave
ML 1010
Cincinnati, OH 45229Phone+1 513-636-4261Fax+1 513-636-3026
Education & Training
Brigham and Women's HospitalFellowship, Hematopathology, 1998 - 1999- Brigham and Women's HospitalResidency, Pathology-Anatomic and Clinical, 1994 - 1998
University of Kansas School of MedicineClass of 1994
Certifications & Licensure
OH State Medical License 2014 - 2026
AR State Medical License 2006 - 2014
TN State Medical License 1999 - 2007
MA State Medical License 1998 - 2000- American Board of Pathology Anatomic Pathology
- American Board of Pathology Hematology
Publications & Presentations
PubMed
- 66 citationsALK+ histiocytosis: a new clinicopathologic spectrum highlighting neurologic involvement and responses to ALK inhibition.Paul Geraeds Kemps, Jennifer Picarsic, Benjamin H. Durham, Zofia Hélias-Rodzewicz, Laura Sophia Hiemcke-Jiwa
Blood. 2021-11-02 - 319 citationsTET1, a member of a novel protein family, is fused to MLL in acute myeloid leukemia containing the t(10;11)(q22;q23)Robert B. Lorsbach, Jennifer Moore, Susan Mathew, Susana C. Raimondi, Suraj Mukatira
Leukemia. 2003-03-01 - 26 citationsLimitations of HLH-2004 criteria in distinguishing malignancy-associated hemophagocytic lymphohistiocytosis.Arun Gurunathan, Alexander A. Boucher, Melissa Mark, Kristina M. Prus, Maureen M. O'Brien
Pediatric Blood & Cancer. 2018-12-01
Abstracts/Posters
- Congenital Dyserythropoietic Anemia Type I Due to Biallelic CDAN1 mutations: Report from the Congenital Dyserythropoietic Anemia Registry (CDAR)Robert B. Lorsbach, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- V2 Trial: A Phase I Study of Venetoclax Combined with CPX-351 for Children, Adolescents and Young Adults with Relapsed or Refractory Acute LeukemiaRobert B. Lorsbach, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- VPS4A mutations Cause a Syndrome with Dyserythropoiesis, Hemolytic Anemia, and Neurodevelopmental DelayRobert B. Lorsbach, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
